HOTH vs REGN · rev $1.24B vs P/E 14, rev $14.34B
Hoth Therapeutics Inc (HOTH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Hoth Therapeutics Inc (HOTH) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported HOTH revenue for 2024-03-31 was $1.24B. Net income was -$2.1M. HOTH currently screens at market cap $15.5M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
HOTH currently screens at market cap $15.5M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the HOTH and REGN stock pages for the full models.
Not investment advice.